Zoetis (ZTS) Expected to Post Earnings on Thursday

Zoetis (NYSE:ZTS) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Zoetis to announce earnings of $1.51 per share and revenue of $2.30 billion for the quarter. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the company posted $1.76 earnings per share. The firm’s revenue for the quarter was down .2% on a year-over-year basis. On average, analysts expect Zoetis to post $6.15 EPS for the current fiscal year and $6.31 EPS for the next fiscal year.

Zoetis Stock Up 4.3%

ZTS opened at $83.18 on Tuesday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company’s 50-day moving average is $75.15 and its 200 day moving average is $93.43. Zoetis has a fifty-two week low of $68.77 and a fifty-two week high of $144.83. The firm has a market capitalization of $34.37 billion, a P/E ratio of 13.70, a PEG ratio of 1.15 and a beta of 0.74.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio is presently 34.93%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ZTS shares. Morgan Stanley decreased their price objective on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a research note on Thursday. Piper Sandler cut their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. BNP Paribas Exane reduced their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Jefferies Financial Group downgraded Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $103.00 to $83.00 in a research report on Tuesday, October 20th. Finally, Zacks Research raised Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Six analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $93.79.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.